Remo CRO


Kalytera identifies sites for planned GvHD clinical trials

04.27 2017.

Kalytera Therapeutics, a clinical-stage biopharmaceutical company developing next-generation cannabinoid- derived therapeutics, has developed the multicenter location component of the plan for the proposed clinical trials to evaluate cannabidiol (CBD) for the prevention and treatment of Graft versus Host Disease (GvHD). Kalytera is developing this clinical trial plan with the intent of obtaining FDA and EMEA […] Details

Study: Site payments, patient reimbursements impact patient centricity

04.27 2017.

Greenphire, an automated clinical payment solutions provider, and the Society for Clinical Research Sites (SCRS) released a new survey that revealed the negative impact that manual payment processes have on global clinical research. Results indicated that manual processes take time away from patient care and shift focus away from research.  The survey of 760 sites […] Details

ACRP, DrugDev partner to increase visibility of clinical researcher and site profiles

04.27 2017.

The Association of Clinical Research Professionals (ACRP) and DrugDev announced a partnership to radically decrease clinical trial investigator burden. The two organizations have partnered together to offer ACRP clinical researchers and site staff members online profiles visible to premier pharma companies and CROs. These companies and CROs represent more than one-third of all clinical trials today […] Details

Device Clinical Trials Present Unique Challenges

04.26 2017.

A clinical trial focused on a device is markedly different than one focused on a drug—a distinction that sometimes gets lost, warns Rob Romanchuk, BHS, CIP, CCRC, CCRCP, vice chair of Schulman IRB. “They’re twin sons of different mothers,” Romanchuk says. “They’re different in nature.” The U.S. Food and Drug Administration emphasizes that the intended […] Details

Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies

04.26 2017.

CARMIEL, Israel, April 18, 2017 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today new, promising results from a preclinical trial conducted in collaboration with Prof. Raphael Schiffmann, Director,… Details

Are Your Job Applicants Lying to You?

04.26 2017.

Are your job applicants lying to you? It may sound like a harsh question, but according to research done by craresources, there are some 7,000 clinical research–related fraudulent resumes in circulation today. We’re not talking about fudging minor details like someone lightly exaggerating his or her role in a previous job. No, we’re talking about […] Details